NasdaqGM:MDWD

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

MediWound Ltd., an integrated biopharmaceutical company, focuses on developing, manufacturing, and commercializing novel therapeutics products to address unmet needs in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders, and other indications.


Snowflake Analysis

Excellent balance sheet with concerning outlook.


Similar Companies

Share Price & News

How has MediWound's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: MDWD's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

-13.1%

MDWD

-0.4%

US Pharmaceuticals

-0.04%

US Market


1 Year Return

18.9%

MDWD

11.8%

US Pharmaceuticals

17.1%

US Market

Return vs Industry: MDWD exceeded the US Pharmaceuticals industry which returned 12.6% over the past year.

Return vs Market: MDWD exceeded the US Market which returned 16.8% over the past year.


Shareholder returns

MDWDIndustryMarket
7 Day-13.1%-0.4%-0.04%
30 Day-7.0%4.8%5.1%
90 Day103.4%2.5%19.5%
1 Year18.9%18.9%14.7%11.8%19.6%17.1%
3 Year-43.2%-43.2%30.3%20.7%42.5%33.3%
5 Year-49.8%-49.8%32.5%17.3%75.1%56.2%

Price Volatility Vs. Market

How volatile is MediWound's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is MediWound undervalued compared to its fair value and its price relative to the market?

9.61x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate MDWD's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate MDWD's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: MDWD is unprofitable, so we can't compare its PE Ratio to the US Pharmaceuticals industry average.

PE vs Market: MDWD is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate MDWD's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: MDWD is overvalued based on its PB Ratio (9.6x) compared to the US Pharmaceuticals industry average (3x).


Next Steps

Future Growth

How is MediWound forecast to perform in the next 1 to 3 years based on estimates from 4 analysts?

-11.1%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: MDWD is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: MDWD is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: MDWD is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: MDWD's revenue (15.3% per year) is forecast to grow faster than the US market (9.4% per year).

High Growth Revenue: MDWD's revenue (15.3% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if MDWD's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has MediWound performed over the past 5 years?

38.9%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: MDWD is currently unprofitable.

Growing Profit Margin: MDWD is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: MDWD is unprofitable, but has reduced losses over the past 5 years at a rate of 38.9% per year.

Accelerating Growth: Unable to compare MDWD's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: MDWD is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (12.1%).


Return on Equity

High ROE: MDWD has a negative Return on Equity (-118.9%), as it is currently unprofitable.


Next Steps

Financial Health

How is MediWound's financial position?


Financial Position Analysis

Short Term Liabilities: MDWD's short term assets ($29.8M) exceed its short term liabilities ($9.8M).

Long Term Liabilities: MDWD's short term assets ($29.8M) exceed its long term liabilities ($14.7M).


Debt to Equity History and Analysis

Debt Level: MDWD is debt free.

Reducing Debt: MDWD has not had any debt for past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: MDWD has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: MDWD has less than a year of cash runway if free cash flow continues to grow at historical rates of 22.4% each year.


Next Steps

Dividend

What is MediWound current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate MDWD's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate MDWD's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if MDWD's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if MDWD's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of MDWD's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

5.8yrs

Average management tenure


CEO

Sharon Malka (48 yo)

1.25yrs

Tenure

US$877,000

Compensation

Mr. Sharon Malka, C.P.A., MBA, serves as Chief Executive officer at MediWound Ltd. since May 31, 2019. He serves as Chief Executive Officer of Bat-AM Company, subsidiary of Clal Biotechnology Industries Lt ...


CEO Compensation Analysis

Compensation vs Market: Sharon's total compensation ($USD877.00K) is above average for companies of similar size in the US market ($USD589.17K).

Compensation vs Earnings: Sharon's compensation has increased whilst the company is unprofitable.


Leadership Team

NamePositionTenureCompensationOwnership
Sharon Malka
Chief Executive Officer1.25yrsUS$877.00k1.17%
$ 1.1m
Lior Rosenberg
Co-Founder & Chief Medical Technology Officer19.58yrsUS$450.00k6.81%
$ 6.6m
Carsten Henke
Chief Commercial Officer of Europe5.83yrsUS$348.00kno data
Ety Klinger
Chief Research & Development Officer6.25yrsUS$410.00kno data
Stephen Wills
Executive Chairman2.83yrsno datano data
Boaz Gur-Lavie
Chief Financial Officer1.17yrsno datano data
Yaron Meyer
Executive VP6.67yrsUS$531.88kno data
Roni Solomon
Controllerno datano datano data

5.8yrs

Average Tenure

54yo

Average Age

Experienced Management: MDWD's management team is seasoned and experienced (5.8 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Stephen Wills
Executive Chairman2.83yrsno datano data
David Fox
Director0.33yrno datano data
Nissim Mashiach
Independent Director3.17yrsno datano data
Sharon Kochan
Independent Director3.17yrsno datano data
Ofer Gonen
Director16.92yrsno datano data
Vickie Driver
Independent Director3.25yrsno datano data
Assaf Segal
Director2.83yrsno datano data
Samuel Moed
Director0.33yrno datano data

3.0yrs

Average Tenure

58yo

Average Age

Experienced Board: MDWD's board of directors are considered experienced (3 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

MediWound Ltd.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: MediWound Ltd.
  • Ticker: MDWD
  • Exchange: NasdaqGM
  • Founded: 2000
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$97.416m
  • Shares outstanding: 27.21m
  • Website: https://www.mediwound.com

Number of Employees


Location

  • MediWound Ltd.
  • 42 Hayarkon Street
  • Yavne
  • 8122745
  • Israel

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
MDWDNasdaqGM (Nasdaq Global Market)YesOrdinary SharesUSUSDMar 2014
M8WDB (Deutsche Boerse AG)YesOrdinary SharesDEEURMar 2014

Biography

MediWound Ltd., an integrated biopharmaceutical company, focuses on developing, manufacturing, and commercializing novel therapeutics products to address unmet needs in the fields of severe burns, chronic ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/08/12 00:37
End of Day Share Price2020/08/11 00:00
Earnings2020/06/30
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.